Off-label GLP-1 use increased fifteenfold between 2021 and 2025, according to a study published Sept. 22 in Obesity. Researchers analyzed medical records from more than 92 million U.S. adults to examine GLP-1 use among patients without a documented condition that…
GLP-1s
Thousands of lawsuits, including at least 4,000 consolidated claims, allege GLP-1 drugs such as Ozempic, Wegovy, Zepbound and Trulicity have caused vision loss, with a recent wave focused specifically on nonarteritic anterior ischemic optic neuropathy, according to a Sept. 21…
About 700,000 new Medicare beneficiaries have started GLP-1 treatment since the Medicare GLP-1 Bridge launched in July, and 70% of those patients are taking Eli Lilly medicines, Lilly CEO Dave Ricks told CNBC in a Sept. 21 interview. The Bridge…
New clinical findings, legal settlements and expanding use cases are shaping the GLP-1 landscape across oncology, pediatrics and addiction care. Here are nine GLP-1 updates to know.
Pharmacies have been seeing compelling interest in Medicare’s GLP-1 Bridge program since its July launch, NPR first reported. The demonstration, designed to give eligible Medicare Part D beneficiaries access to certain GLP-1s at a fixed monthly cost, will run through…
Advertisement
Santa Fe, N.M.-based Quel Health launched a telehealth platform focused on using GLP-1 receptor agonists in addiction care. The platform is available in 41 states and the District of Columbia, with national coverage planned by year-end, according to a Sept.…
Novo Nordisk has secured a permanent injunction restricting LifeRxMD from making certain claims involving Ozempic, Wegovy and Rybelsus in its marketing of compounded drugs. The injunction was entered as part of a confidential settlement between Novo Nordisk and LifeRxMD, according…
Two out of every 5 young children who took Novo Nordisk’s weight-loss drug Wegovy in a clinical trial lost enough weight to no longer be classified as having obesity, the drugmaker announced Sept. 7. When combined with diet and exercise,…
The FDA is warning patients and healthcare professionals about safety and quality concerns involving compounded GLP-1 drugs and unapproved weight-loss drugs as adverse event reports involving compounded semaglutide and tirzepatide surpass 1,700. Here are four things to know:
GLP-1 use among young children with obesity remains rare but increased rapidly from 2019 to 2026, according to a study published Sept. 4 in Pediatrics. Here are five things to know: